Drug recall · September 8, 2021
Naproxen Sodum Tablets USP 220 mg recall
Why: CGMP Deviations
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Naproxen Sodum Tablets USP 220 mg, (Caplet), Manufactured by: Granules India Limited, Sy.No. 160/A, 161/E, 162, &174/A, Gagillapur Village, Dundigal-Gandimalsamma Monday, Medchai-Maikhajgir District - 500043, Telangana, INDIA. NDC 62207-762-36
- Lots / codes
7620060a
- Quantity
- 11,450,000 tablets
- Company
- Granules USA, Inc., Parsippany, NJ
- Distribution
- NY
- Initiated
- August 11, 2021 · Voluntary: Firm initiated
- Classified
- August 27, 2021
- Reported
- September 8, 2021
- Ended
- February 16, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Naproxen
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.